Healthcare Hedge Fund Calls Valeant Pricing “Outrageous” While Recommending Horizon

Mark Melin

Published onNovember 5, 2015

Updated on May 13, 2021

At this moment, there are significant investing opportunities in healthcare, Jim Flynn of Deerfield Partners said at the Invest for Kids Conference in Chicago Wednesday. Yet Valeant Pharmaceuticals is not one of them, he emphatically asserted as he outlined a potential relative value trade when he recommended a long investment in Horizon Pharmaceuticals.

Table of Contents

Horizon Pharmaceuticals VS Valeant VRX stock price and P/E ratio — Chart via S&P CapIQ

Flynn: Valeant pushes financial structuring to its limit and pricing issues are more a statement on individual companies than pharma industry as a whole

Deerfield Partners is a well-regarded healthcare specialty hedge fund that has delivered to investors 38 times...

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article

Already a member? Log in here

Mark Melin

Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.

Healthcare Hedge Fund Calls Valeant Pricing “Outrageous” While Recommending Horizon

Flynn: Valeant pushes financial structuring to its limit and pricing issues are more a statement on individual companies than pharma industry as a whole

Login required to continue reading.

Get Your Business News